Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists

Author affiliations

Abstract

Close structural analogues of 5-carboxamidotryptamine (5-CT) based on the newly discovered indole–imidazole scaffold were synthesized and evaluated to search for a 5-HT7 receptor agonist of higher selectivity. In vitro drug-likeness studies and in vivo pharmacological evaluation of potent and selective low-basicity 5-HT7 receptor agonists, previously published 7 (3-(1-ethyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide, AH-494) and 13 (3-(1-methyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide), have supported their usefulness as pharmacological tools. Comprehensive in vitro comparison studies between 7, 13 and the commonly used 5-CT showed their very similar ADMET properties. Compound 7 at 1 mg kg−1 reversed MK-801-induced disruption in novel object recognition in mice and alleviated stress-induced hyperthermia (SIH) at high doses. Taking into account both in vitro and in vivo data, 7 and 13 may be considered as alternatives to 5-CT as pharmacological tools with important additional benefit associated with their low-basicity: high selectivity over 5-HT1AR.

Graphical abstract: Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Jun 2018, accepted on 21 Sep 2018 and first published on 25 Sep 2018


Article type: Research Article
DOI: 10.1039/C8MD00313K
Citation: Med. Chem. Commun., 2018,9, 1882-1890
  •   Request permissions

    Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists

    G. Latacz, A. S. Hogendorf, A. Hogendorf, A. Lubelska, J. M. Wierońska, M. Woźniak, P. Cieślik, K. Kieć-Kononowicz, J. Handzlik and A. J. Bojarski, Med. Chem. Commun., 2018, 9, 1882
    DOI: 10.1039/C8MD00313K

Search articles by author

Spotlight

Advertisements